2/12/2020 – RespireRx Pharmaceuticals Inc. Progress and Status Report February 12, 2020j3ff1 Read More
2/5/2020 – RespireRx Pharmaceuticals Inc. Announces the Filing of Broad Enabling Cannabinoid Continuation-in-Part and New Provisional Patent Applications February 5, 2020j3ff1 Read More
2/3/2020 – RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors February 3, 2020j3ff1 Read More
9/9/2019 – RespireRx Pharmaceuticals Inc. Executives Participating in the 2nd Annual International Cannabinoid Derived Pharmaceuticals Summit September 10, 2019j3ff1 Read More
7/30/2019 – RespireRx Pharmaceuticals Inc. Send Notice Letter to the Board of Directors of Therapix Biosciences Ltd. July 30, 2019j3ff1 Read More
2/19/2019 – RespireRx Pharmaceuticals Inc. and Impression Healthcare Limited Announce Agreement to Explore Commercialization of Dronabinol for the Treatment of Obstructive Sleep Apnea in Australia, New Zealand and Southeast Asia February 19, 2019j3ff1 Read More
1/3/2019 – RespireRx Pharmaceuticals Inc. Appoints James Sapirstein as Executive Vice Chairman of the Board of Directors January 3, 2019j3ff1 Read More
12/10/2018 – RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit,December 10 – 12, 2018 December 10, 2018j3ff1 Read More
09/10/18 – RespireRx Pharmaceuticals Inc. Secures Clinical and Commercial Supply of Dronabinol for Obstructive Sleep Apnea with the Signing of a Development and Supply Agreement with Noramco, Inc. September 10, 2018j3ff1 Read More
07/25/2018 – RespireRx Pharmaceuticals Inc. Announces Publication of Ampakine Data: Effects of Chronic Systemic Low-impact Ampakine Treatment on Neurotrophin Expression in Rat Brain July 25, 2018j3ff1 Read More
